Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone

A randomized placebo-controlled trial

Giuseppe Derosa, Ivano G. Franzetti, Fabrizio Querci, Anna Carbone, Leonardina Ciccarelli, Mario N. Piccinni, Elena Fogari, Pamela Maffioli

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

STUDY OBJECTIVE To evaluate the effects of exenatide on some inflammatory markers and to quantify the effect of exenatide on b-cell function. DESIGN A randomized, double-blind, placebo-controlled trial. SETTING Seven hospitals in Italy. PATIENTS A total of 174 white treatment-naive adults with type 2 diabetes and a glycated hemoglobin (HbA1c) level higher than 7.5%. INTERVENTION After an open-label run-in period of 8-2 months with metformin, patients were randomized to take exenatide (5 lg twice/day for the first 4 weeks, 10 lg twice/day thereafter) or a placebo volume equivalent for 12 months. MEASUREMENTS AND MAIN RESULTS Body mass index, HbA1c, fasting plasma glucose, postprandial plasma glucose, fasting plasma insulin (FPI), homeostasis model assessment insulin resistance index, homeostasis model assessment b-cell function index (HOMA-b), fasting plasma proinsulin (FPPr), proinsulin-to-fasting plasma insulin ratio (Pr:FPI ratio), C-peptide, glucagon, vaspin, chemerin, and resistin were evaluated at baseline, at randomization, and at 3, 6, 9, and 12 months. Patients also underwent a combined euglycemic, hyperinsulinemic, and hyperglycemic clamp with subsequent arginine stimulation to assess insulin sensitivity and insulin secretion. HbA1c was significantly improved with exenatide plus metformin compared with placebo plus metformin. Exenatide plus metformin was also significantly more effective than placebo plus metformin in increasing HOMA-b C-peptide, and all measures of b-cell function after the euglycemic hyperinsulinemic and hyperglycemic clamp. We observed that exenatide plus metformin also reduced resistin compared with placebo plus metformin. No variations in vaspin and chemerin were noted in group-to-group comparisons. We observed a significant correlation between M value increase, an index of insulin sensitivity, and a decrease in inflammatory parameters in the exenatide plus metformin group. CONCLUSIONS The combination of exenatide plus metformin was more effective than metformin alone in improving glycemic control, b-cell function, and inflammatory parameters.

Original languageEnglish
Pages (from-to)817-826
Number of pages10
JournalPharmacotherapy
Volume33
Issue number8
DOIs
Publication statusPublished - Aug 2013

Fingerprint

Metformin
Randomized Controlled Trials
Placebos
Fasting
Resistin
Therapeutics
Insulin Resistance
Proinsulin
Homeostasis
C-Peptide
Insulin
exenatide
Glucose
Glycosylated Hemoglobin A
Random Allocation
Glucagon
Type 2 Diabetes Mellitus
Italy
Arginine
Body Mass Index

Keywords

  • Chemerin
  • Exenatide
  • Glycemic control
  • Inflammation
  • Metformin
  • Resistin
  • Vaspin

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone : A randomized placebo-controlled trial. / Derosa, Giuseppe; Franzetti, Ivano G.; Querci, Fabrizio; Carbone, Anna; Ciccarelli, Leonardina; Piccinni, Mario N.; Fogari, Elena; Maffioli, Pamela.

In: Pharmacotherapy, Vol. 33, No. 8, 08.2013, p. 817-826.

Research output: Contribution to journalArticle

Derosa, Giuseppe ; Franzetti, Ivano G. ; Querci, Fabrizio ; Carbone, Anna ; Ciccarelli, Leonardina ; Piccinni, Mario N. ; Fogari, Elena ; Maffioli, Pamela. / Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone : A randomized placebo-controlled trial. In: Pharmacotherapy. 2013 ; Vol. 33, No. 8. pp. 817-826.
@article{cdbb7fd27a3f4eafa2f4a1d1c0ae59a0,
title = "Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: A randomized placebo-controlled trial",
abstract = "STUDY OBJECTIVE To evaluate the effects of exenatide on some inflammatory markers and to quantify the effect of exenatide on b-cell function. DESIGN A randomized, double-blind, placebo-controlled trial. SETTING Seven hospitals in Italy. PATIENTS A total of 174 white treatment-naive adults with type 2 diabetes and a glycated hemoglobin (HbA1c) level higher than 7.5{\%}. INTERVENTION After an open-label run-in period of 8-2 months with metformin, patients were randomized to take exenatide (5 lg twice/day for the first 4 weeks, 10 lg twice/day thereafter) or a placebo volume equivalent for 12 months. MEASUREMENTS AND MAIN RESULTS Body mass index, HbA1c, fasting plasma glucose, postprandial plasma glucose, fasting plasma insulin (FPI), homeostasis model assessment insulin resistance index, homeostasis model assessment b-cell function index (HOMA-b), fasting plasma proinsulin (FPPr), proinsulin-to-fasting plasma insulin ratio (Pr:FPI ratio), C-peptide, glucagon, vaspin, chemerin, and resistin were evaluated at baseline, at randomization, and at 3, 6, 9, and 12 months. Patients also underwent a combined euglycemic, hyperinsulinemic, and hyperglycemic clamp with subsequent arginine stimulation to assess insulin sensitivity and insulin secretion. HbA1c was significantly improved with exenatide plus metformin compared with placebo plus metformin. Exenatide plus metformin was also significantly more effective than placebo plus metformin in increasing HOMA-b C-peptide, and all measures of b-cell function after the euglycemic hyperinsulinemic and hyperglycemic clamp. We observed that exenatide plus metformin also reduced resistin compared with placebo plus metformin. No variations in vaspin and chemerin were noted in group-to-group comparisons. We observed a significant correlation between M value increase, an index of insulin sensitivity, and a decrease in inflammatory parameters in the exenatide plus metformin group. CONCLUSIONS The combination of exenatide plus metformin was more effective than metformin alone in improving glycemic control, b-cell function, and inflammatory parameters.",
keywords = "Chemerin, Exenatide, Glycemic control, Inflammation, Metformin, Resistin, Vaspin",
author = "Giuseppe Derosa and Franzetti, {Ivano G.} and Fabrizio Querci and Anna Carbone and Leonardina Ciccarelli and Piccinni, {Mario N.} and Elena Fogari and Pamela Maffioli",
year = "2013",
month = "8",
doi = "10.1002/phar.1301",
language = "English",
volume = "33",
pages = "817--826",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "8",

}

TY - JOUR

T1 - Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone

T2 - A randomized placebo-controlled trial

AU - Derosa, Giuseppe

AU - Franzetti, Ivano G.

AU - Querci, Fabrizio

AU - Carbone, Anna

AU - Ciccarelli, Leonardina

AU - Piccinni, Mario N.

AU - Fogari, Elena

AU - Maffioli, Pamela

PY - 2013/8

Y1 - 2013/8

N2 - STUDY OBJECTIVE To evaluate the effects of exenatide on some inflammatory markers and to quantify the effect of exenatide on b-cell function. DESIGN A randomized, double-blind, placebo-controlled trial. SETTING Seven hospitals in Italy. PATIENTS A total of 174 white treatment-naive adults with type 2 diabetes and a glycated hemoglobin (HbA1c) level higher than 7.5%. INTERVENTION After an open-label run-in period of 8-2 months with metformin, patients were randomized to take exenatide (5 lg twice/day for the first 4 weeks, 10 lg twice/day thereafter) or a placebo volume equivalent for 12 months. MEASUREMENTS AND MAIN RESULTS Body mass index, HbA1c, fasting plasma glucose, postprandial plasma glucose, fasting plasma insulin (FPI), homeostasis model assessment insulin resistance index, homeostasis model assessment b-cell function index (HOMA-b), fasting plasma proinsulin (FPPr), proinsulin-to-fasting plasma insulin ratio (Pr:FPI ratio), C-peptide, glucagon, vaspin, chemerin, and resistin were evaluated at baseline, at randomization, and at 3, 6, 9, and 12 months. Patients also underwent a combined euglycemic, hyperinsulinemic, and hyperglycemic clamp with subsequent arginine stimulation to assess insulin sensitivity and insulin secretion. HbA1c was significantly improved with exenatide plus metformin compared with placebo plus metformin. Exenatide plus metformin was also significantly more effective than placebo plus metformin in increasing HOMA-b C-peptide, and all measures of b-cell function after the euglycemic hyperinsulinemic and hyperglycemic clamp. We observed that exenatide plus metformin also reduced resistin compared with placebo plus metformin. No variations in vaspin and chemerin were noted in group-to-group comparisons. We observed a significant correlation between M value increase, an index of insulin sensitivity, and a decrease in inflammatory parameters in the exenatide plus metformin group. CONCLUSIONS The combination of exenatide plus metformin was more effective than metformin alone in improving glycemic control, b-cell function, and inflammatory parameters.

AB - STUDY OBJECTIVE To evaluate the effects of exenatide on some inflammatory markers and to quantify the effect of exenatide on b-cell function. DESIGN A randomized, double-blind, placebo-controlled trial. SETTING Seven hospitals in Italy. PATIENTS A total of 174 white treatment-naive adults with type 2 diabetes and a glycated hemoglobin (HbA1c) level higher than 7.5%. INTERVENTION After an open-label run-in period of 8-2 months with metformin, patients were randomized to take exenatide (5 lg twice/day for the first 4 weeks, 10 lg twice/day thereafter) or a placebo volume equivalent for 12 months. MEASUREMENTS AND MAIN RESULTS Body mass index, HbA1c, fasting plasma glucose, postprandial plasma glucose, fasting plasma insulin (FPI), homeostasis model assessment insulin resistance index, homeostasis model assessment b-cell function index (HOMA-b), fasting plasma proinsulin (FPPr), proinsulin-to-fasting plasma insulin ratio (Pr:FPI ratio), C-peptide, glucagon, vaspin, chemerin, and resistin were evaluated at baseline, at randomization, and at 3, 6, 9, and 12 months. Patients also underwent a combined euglycemic, hyperinsulinemic, and hyperglycemic clamp with subsequent arginine stimulation to assess insulin sensitivity and insulin secretion. HbA1c was significantly improved with exenatide plus metformin compared with placebo plus metformin. Exenatide plus metformin was also significantly more effective than placebo plus metformin in increasing HOMA-b C-peptide, and all measures of b-cell function after the euglycemic hyperinsulinemic and hyperglycemic clamp. We observed that exenatide plus metformin also reduced resistin compared with placebo plus metformin. No variations in vaspin and chemerin were noted in group-to-group comparisons. We observed a significant correlation between M value increase, an index of insulin sensitivity, and a decrease in inflammatory parameters in the exenatide plus metformin group. CONCLUSIONS The combination of exenatide plus metformin was more effective than metformin alone in improving glycemic control, b-cell function, and inflammatory parameters.

KW - Chemerin

KW - Exenatide

KW - Glycemic control

KW - Inflammation

KW - Metformin

KW - Resistin

KW - Vaspin

UR - http://www.scopus.com/inward/record.url?scp=84885231257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885231257&partnerID=8YFLogxK

U2 - 10.1002/phar.1301

DO - 10.1002/phar.1301

M3 - Article

VL - 33

SP - 817

EP - 826

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 8

ER -